pkc inhibitor peptide peptide inhibitor - planet-peptide-reviews-consumer-reports inhibitor Understanding PKC Inhibitor Peptides: A Deep Dive into Their Mechanism and Applications

rhode-by-hailey-bieber-peptide-glazing-fluid PKC inhibitor peptide research is a rapidly evolving field, focusing on compounds that selectively target and modulate the activity of Protein Kinase C (PKC) enzymes. PKC is a crucial family of serine/threonine kinases involved in a wide array of cellular signal transduction pathways, influencing processes like cell growth, differentiation, apoptosis, and immune responsesProtein Kinase C Inhibitor - an overview | ScienceDirect Topics. Understanding how PKC inhibitor peptides function and their potential applications is vital for researchers and clinicians alikePKCε Translocation Inhibitor Peptide, Negative Control.

The Nature of PKC Inhibitor Peptides

PKC inhibitor peptides are typically short chains of amino acids designed to interfere with the function of PKC enzymes. These peptides can be broadly categorized into two main types, as highlighted in scientific literature:

1.PKCε Translocation Inhibitor Peptide, Negative Control Peptides derived from PKC protein fragments: These peptides often mimic natural regulatory regions of the PKC enzyme itself. A prime example is the Protein Kinase C (19-31) peptide, which is derived from the pseudo-substrate regulatory domain of PKCa.Protein kinase Cepsilon,PKC(e), is involved in the regulation of diverse cellular functions including neurotransmitter release in the brain. Translocation of ... By binding to the active sites of protein kinase C, these peptides act as pseudosubstrates, competitively inhibiting the enzyme's ability to phosphorylate its natural targets. The PKC pseudosubstrate inhibitor is another example, which is a cell-permeable, reversible, and myristoylated peptide inhibitor of protein kinase C ζ.

2. Peptides obtained by mutation of phosphorylation sites: These peptides are engineered through modifications to known PKC substratesPKCd (8-17), PKCd Inhibitor - 1 mg. By altering key phosphorylation sites, these peptides can effectively block the kinase's activityeV1-2 is a selective εPKCinhibitor peptidewhich interferes with protein-protein interactions between the ϵPKC isozyme and its anchoring protein (ϵRACK)..

The specificity of these inhibitors is a critical aspect.作者：M Zerihun·2023·被引用次数：10—This approach has proven successful for theinhibitionof actions of specific isoforms ofprotein kinase C(PKC) [62,63]. (2)Peptidesderived from similarity ... For instance, epsilon-V1-2, epsilon-PKC Inhibitor is a peptide that specifically inhibits epsilon-PKC by disrupting its binding to its receptor, RACK2PKC Isoenzyme Inhibitor / PKC(e) translocation peptide. Similarly, PKC ε Translocation Inhibitor Peptide is designed to selectively block the translocation of PKC ε. The development of rationally designed peptide regulators of protein kinase C aims to create highly specific inhibitors by targeting the interaction sites between specific PKC isozymes and their receptors.

Mechanisms of Inhibition and Specific Parameters

The mechanism of action for PKC inhibitor peptides is primarily through competitive inhibition or by disrupting essential protein-protein interactions.PKCεInhibitor Peptideis a high quality research product available for a wide array of chemical, biochemical and immunological applications.

* Pseudosubstrate Inhibition: As mentioned, many PKC peptide inhibitors function as pseudosubstrates作者：AS Bogard·2015·被引用次数：40—In this study, we demonstrated that ZIP interacts with conventional and novelPKC, in addition to atypicalPKCisoforms.. They possess sequences that resemble the natural substrates of PKC but are unable to be phosphorylated or lead to a non-functional complex. For example, PKC β pseudosubstrate (1792), consisting of amino acids 19-31 of PKC, exhibits a selective cell-permeable inhibition of protein kinase C with an IC50 of approximately 0.5 μMPKC Pseudosubstrate Inhibitor. Similarly, PKC (19-35) Peptide acts as a PKC pseudosubstrate inhibitor, potentially blocking the substrate-binding siteAPKC inhibitoris defined as a compound that specifically targets protein kinase C (PKC), a family of serine/threonine kinases involved in cell signaling ....

* Disruption of Translocation: Some peptides target the translocation of PKC to specific cellular compartments, a critical step in its activation. The PKC ε Translocation Inhibitor Peptide is an example of an inhibitor used to control the biological activity of PKC ε. These inhibitors can be crucial for studying the role of PKC in specific cellular compartments.

* Disruption of Protein-Protein Interactions: Certain peptides interfere with the binding of PKC to its regulatory or anchoring proteins. eV1-2, a selective εPKC inhibitor peptide, interferes with interactions between the εPKC isozyme and its anchoring protein (εRACK).Protein Kinase C(19-31), apeptide inhibitorofprotein kinase C(PKC), derived from the pseudo-substrate regulatory domain of PKCa (residues 19-31), ...

Key parameters associated with these inhibitor peptides are crucial for their application in research:

* Purity: High purity, often ≥97%, is essential for reliable experimental results. For example, PKC ε inhibitor peptide is available with a purity of ≥97%.

* Molecular Weight: The molecular weight is a fundamental characteristic.Thispeptidespecifically inhibits epsilon-PKCby disruptingPKCbinding to its receptor, RACK2. epsilonPKC mediated signal transduction plays a role in cell ... For instance, a specific PKC ε inhibitor peptide has a molecular weight of 844PKCɛinhibitor peptideis a syntheticpeptidecorresponding to an amino acid sequence found in the amino terminal C2 domain of most mammalian forms of PKCɛ..

* Inhibitory Potency (IC50/Ki): The concentration at which a peptide inhibits 50% of enzyme activity (IC50) or the dissociation constant (Ki) quantifies its potency.PKCε TranslocationInhibitor Peptide, Negative Control - Calbiochem The PKCε TranslocationInhibitor Peptide, Negative Control controls the biological ... One PKC inhibitor active peptide demonstrates potent inhibition of PKC with a Ki of 0Peptides as Allosteric Protein Kinase C Modulators ....15 μM, showing no significant inhibition of cAMP-dependent protein kinases (IC50 > 400 μM), highlighting its selectivityThispeptideis derived from the V1 domain ofprotein kinase C(PKC)d. It inhibits phorbol 12-myristate 13-acetate (PMA)-induced PKCd translocation and ....

* Selectivity: The ability of a peptide inhibitor to target specific PKC isoforms while sparing others is highly desirable.PKC inhibitoris an activepeptidepotent inhibitor of PKC (Ki of 0.15 μM); no significant inhibition of cAMP-dependent protein kinases (IC50>400 μM) PKC β pseudosubstrate is a selective peptide inhibitor of protein kinase CPKC Inhibitor Peptide 19-36 | 539560.

Applications and Research Significance

The development and study of PKC inhibitor peptides have significant implications across various research areas.

* Cell Signaling Research: These peptides serve as invaluable tools for dissecting the complex signaling pathways mediated by protein kinase C. By selectively inhibiting specific isoforms, researchers can elucidate their unique roles in cellular processes. For instance, studying the inhibition of PKC ε translocation helps understand its involvement in neurotransmitter release in the brainActivators and Inhibitors of Protein Kinase C (PKC) - PMC - NIH.

* Disease Research: Given PKC's involvement in numerous diseases, including cancer, inflammation, and neurological disorders, PKC inhibitors are being explored as potential therapeutic agentsPKCβ pseudosubstrate is a selective cell-permeablepeptide inhibitorofprotein kinase C(IC50 ~ 0.5 μM). Consists of amino acids 19 - 31 ofPKC.... The precise targeting offered by peptide inhibitors holds promise for developing more effective and less toxic treatments.

* Drug Development: Understanding the structure-activity relationships of PKC inhibitor peptides can guide the design of novel small molecule inhibitors with improved pharmacokinetic properties and oral bioavailability.

While some specific products like PKC Inhibitor Peptide 19-36 have been discontinued, the research into PKC inhibitor peptides continues, with ongoing efforts to discover and develop new, potent, and selective inhibitors for a wide range of applications in biological and medical research. The exploration of peptides targeting protein kinases remains a dynamic and promising area of scientific inquiry.